CHOP Plus Zevalin (REG) Therapy Shows Efficacy In Elderly Patients With Most Common Type Of Aggressive Non-Hodgkin’s Lymphoma
- Wednesday, December 27, 2006, 14:31
- Lymphoma / Leukemia, Seniors / Aging
- 4 views
- Add a comment
A study undertaken by the University of Bologna, Italy, was presented at the 48th Annual Meeting of the American Society of Haematology (ASH) in Orlando, USA, that demonstrates an innovative treatment regimen for Non-Hodgkin’s Lymphoma (NHL) may help improve the quality of responses to treatment of elderly patients suffering from the most common type of aggressive NHL, Diffuse Large-B-cell Lymphoma (DLBCL)(1). Zevalin (90Y Ibritumomab Tiuxetan) treatment was given to patients as a first-line consolidation therapy after patients had received standard chemotherapy. The study showed that four out of five elderly patients (80%) boosted the quality of their response from a Partial Response (PR) to a Complete Response (CR) when Zevalin was administered as first-line consolidation therapy.
“The aim of consolidation therapy is to improve the quality of response already achieved by the first-line treatment. These data are promising as they show Zevalin can increase the complete remission rates when used as a consolidation therapy in elderly DLBCL patients. Elderly patients may be less able to tolerate the toxicities associated with conventional chemotherapies, so ensuring that first-line responses are maximised is important in treating DLBCL, where a complete cure is the goal.” Commented Professor Pier Luigi Zinzani, Institute of Haematology and Medical Oncology, University of Bologna.
The single arm, phase II study evaluated the efficacy and safety of Zevalin in 20 patients over 60 years of age. Patients who were previously untreated received CHOP chemotherapy (cyclophosphamide, doxorubicin; vincristine and prednisone) and those achieving at least a partial remission (PR) after 6 cycles of CHOP chemotherapy went on to receive consolidation treatment with Zevalin. Results showed that all patients achieved a response after receiving CHOP treatment: 75% (15 patients) achieved a CR and 25% (5 patients) achieved a PR. Following Zevalin consolidation therapy, 4 out of 5 patients (80%) converted from a PR to a CR.
“Cancer patients can suffer from two things: their disease and their chemotherapy side effects. The next step is to see if we can reduce the cycles of chemotherapy and add in Zevalin for these patients, in order to retain or boost the complete response rates, while lessening a patient’s exposure to the toxicities of chemotherapies.” Commented Professor Zinzani.
While the CHOP chemotherapy regimen has been standard of care for NHL patients for many years, the recent advent of rituximab has meant this drug has now become an addition to standard CHOP therapy (R-CHOP). Professor Zinzani continued: “The next clinical question is to investigate the efficacy of Zevalin when used as a first-line consolidation treatment in DLBCL patients who receive rituximab-containing chemotherapy regimens.”
Zevalin was generally well tolerated, neutropenia was the most common adverse event.
About the Author
Write a Comment
Gravatars are small images that can show your personality. You can get your gravatar for free today!
You must be logged in to post a comment.